Pilot Study of EGFR Inhibition With Erlotinib in Cirrhosis to Inhibit Fibrogenesis and Prevent Hepatocellular Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Erlotinib (Primary)
- Indications Fibrosis; Liver cancer; Liver cirrhosis
- Focus Therapeutic Use
- 29 Dec 2017 Planned End Date changed from 1 Jan 2018 to 1 Aug 2018.
- 29 Dec 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Aug 2018.
- 10 Jun 2017 Biomarkers information updated